The expanding role of the pharmacist in the management of hepatitis C infection

Journal of Managed Care Pharmacy

Volumn 17, Issue 9, 2011, Pages 709-712

  Spooner, Linda M ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR;

ANEMIA; ANORECTAL DISEASE; DRUG SAFETY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NOTE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PHARMACIST; PHARMACY; PRESCRIPTION; RASH; TASTE DISORDER; TREATMENT REFUSAL; TREATMENT RESPONSE;

EID: 84856250399     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2011.17.9.709     Document Type: Note

References (10)

1. World Health Organization. Hepatitis C. Fact sheet no. 164. June 2011. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed October 21, 2011.
2. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513-21.
3. Tungol A, Rademacher KA, Schafer JA. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus. J Manag Care Pharm. 2011;17(9):685-94.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74.
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65.
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-82. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa020047. Accessed October 21, 2011.
7. Hadziyannis SJ, Sette H Jr, Morgan TR, et al; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346-55.
8. Victrelis (boceprevir) capsules. Merck. May 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf. Accessed October 21, 2011.
9. Incivek (telaprevir) film coated tablets. Vertex. May 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf. Accessed October 21, 2011.
10. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-44.